<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>MFUM-BrTNBC-1, a newly established patient-derived triple-negative breast cancer cell line</dc:title><dc:creator>Skok,	Kristijan	(Avtor)
	</dc:creator><dc:creator>Gradišnik,	Lidija	(Avtor)
	</dc:creator><dc:creator>Čelešnik,	Helena Sabina	(Avtor)
	</dc:creator><dc:creator>Milojević,	Marko	(Avtor)
	</dc:creator><dc:creator>Potočnik,	Uroš	(Avtor)
	</dc:creator><dc:creator>Jezernik,	Gregor	(Avtor)
	</dc:creator><dc:creator>Gorenjak,	Mario	(Avtor)
	</dc:creator><dc:creator>Sobočan,	Monika	(Avtor)
	</dc:creator><dc:creator>Takač,	Iztok	(Avtor)
	</dc:creator><dc:creator>Kavalar,	Rajko	(Avtor)
	</dc:creator><dc:creator>Maver,	Uroš	(Avtor)
	</dc:creator><dc:subject>hormonal receptors</dc:subject><dc:subject>MFUM-BrTNBC-1</dc:subject><dc:subject>MCF-7</dc:subject><dc:subject>MDA-MB-231</dc:subject><dc:subject>MDA-MB-453</dc:subject><dc:description>Triple-negative breast cancer (TNBC) is a breast cancer (BC) subtype that accounts for
approximately 15–20% of all BC cases. Cancer cell lines (CLs) provide an efficient way to model the
disease. We have recently isolated a patient-derived triple-negative BC CL MFUM-BrTNBC-1 and
performed a detailed morphological and molecular characterisation and a comprehensive comparison
with three commercial BC CLs (MCF-7, MDA-MB-231, MDA-MB-453). Light and fluorescence
microscopy were used for morphological studies; immunocytochemical staining for hormone receptor,
p53 and Ki67 status; RNA sequencing, qRT-PCR and STR analysis for molecular characterisation; and
biomedical image analysis for comparative phenotypical analysis. The patient tissue-derived MFUMBrTNBC-1 maintained the primary triple-negative receptor status. STR analysis showed a stable and
unique STR profile up to the 6th passage. MFUM-BrTNBC-1 expressed EMT transition markers and
displayed changes in several cancer-related pathways (MAPK, Wnt and PI3K signalling; nucleotide
excision repair; and SWI/SNF chromatin remodelling). Morphologically, MFUM-BrTNBC-1 differed
from the commercial TNBC CL MDA-MB-231. The advantages of MFUM-BrTNBC-1 are its isolation
from a primary tumour, rather than a metastatic site; good growth characteristics; phenotype identical
to primary tissue; complete records of origin; a unique identifier; complete, unique STR profile;
quantifiable morphological properties; and genetic stability up to (at least) the 6th passage.</dc:description><dc:publisher>MDPI AG</dc:publisher><dc:date>2022</dc:date><dc:date>2025-04-10 11:21:27</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>92461</dc:identifier><dc:identifier>UDK: 618.19-006</dc:identifier><dc:identifier>COBISS_ID: 91552259</dc:identifier><dc:identifier>DOI: 10.3390/cells11010117</dc:identifier><dc:identifier>ISSN pri članku: 2073-4409</dc:identifier><dc:language>sl</dc:language><dc:rights>© 2021 by the authors</dc:rights></metadata>
